From CAR-T therapies and Artificial Intelligence (AI) to the enactment of the Drug Supply Chain Security Act (DSCSA), the past five years has seen transformative change for the industry. With innovation in drug development leading more complex and increasingly targeted therapies for smaller patient populations, manufacturing challenges have emerged requiring technically advanced solutions.

Contract Pharma sat down with Pfizer CentreOnes’ general manager, JoyL Silva, and other industry leaders to consider how business operations have evolved to accommodate changing industry need and what we can expect for the future of the industry and outsourcing.

Read the full article here.